

JUBILANT PHARMA LIMITED
(Company Registration No. 200506887H)
(Incorporated in the Republic of Singapore)
Registered office: 80 Robinson Road, #02-00, Singapore 068898

December 8, 2018

Singapore Exchange Securities Trading Limited

11 North Buona Vista Drive #06-07
The Metropolis Tower 2
Singapore 138589

Dear Sirs,

We enclose a communication pertaining to USFDA inspection.

This is for your kind information and records.

Thanking you,

Yours faithfully,
For Jubilant Pharma Limited



Arun Kumar Sharma
Chief Financial Officer

**Jubilant Pharma Ltd.**

6 Temasek Boulevard, #20-06
Suntec City Tower Four, Singapore 038986
Tel.: +65 6235 4129
www.jubilantpharma.com

USFDA inspection update – solid dosage formulation facility at Roorkee, India

Noida (UP), India, Saturday, Dec 8, 2018

Jubilant Pharma Limited (JPL), a material wholly owned subsidiary of Jubilant Life Sciences Ltd, India, has announced that in response to the USFDA inspection conducted at its Roorkee, India facility of solid dosage formulations during August 2018, the agency has informed to classify the inspection as “Official Action Indicated” (OAI) and that approvals of pending applications or supplements from this site maybe withheld. However, this will not have any impact on the existing revenues from operations from this facility.

We believe that this letter has been issued as part of USFDA initiative to respond to the company within 90 days of the inspection, regarding the status. As per the guidelines, the company can engage within 40 days to get the agency’s decision downgraded from classifying as OAI. Jubilant is in the process of sending further update of its corrective actions and remains hopeful of a positive outcome.

About Jubilant Pharma Limited

Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly owned subsidiary of Jubilant Life Sciences Limited, is an integrated global Pharmaceutical company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non Sterile products. JPL has 6 USFDA approved manufacturing facilities in India, US and Canada and R&D centres in India and Canada. The Company has a team of around 3,500 multicultural people across the globe and is committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally.

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant may, from time to time, make additional written and oral forward looking statements, including statements contained in the company’s filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors. For detailed disclaimer in case of Jubilant Pharma Limited, please visit <http://www.jubilantpharma.com/fullpage.aspx?mpgid=1147&pgid=1147>